News Releases
Jul 8 2003
Peregrine's Vasopermeation Enhancement Agent Technology Highlighted In The Lancet Oncology
Jul 1 2003
Peregrine Announces Fiscal Year 2003 Year End Results And Operational Highlights
Jun 27 2003
Peregrine Pharmaceuticals Receives Over $4 Million in Cash
Jun 23 2003
Peregrine's Vasopermeation Enhancement Agent Technology Highlighted In Nature Reviews Cancer
Jun 20 2003
Peregrine's Phosphatidylserine Based Vascular Targeting Agent Technology Presented at the Angiogenesis II Conference in Paris, France
Jun 18 2003
Peregrine and Affitech to Collaborate on Developing Fully Human Vascular Targeting Agent Antibodies
Jun 12 2003
Peregrine Regains Compliance with Nasdaq Listing Requirements
Jun 9 2003
Peregrine Pharmaceuticals Raises Over $2 Million From Institutional Investors; $1.5 Million In Debt Converted
Jun 4 2003
Peregrine's Vascular Targeting Agent Effective In Combination Cancer Therapy
May 21 2003
Peregrine's Vasopermeation Enhancement Agent Technology Published In Journal Of The National Cancer Institute